Richard T. Maziarz, M.D.
- Professor of Medicine, School of Medicine
Biography
Dr Maziarz has been involved in clinical investigation and translational research, for over three decades, beginning with research and clinical training at the Dana-Farber Cancer Institute and the Brigham & Women’s Hospital and continuing in 1991 when he moved to OHSU to develop a transplantation immunology program and served as the medical director of the adult OHSU stem cell transplant program since 1994.
His research involved the immunology of transplantation or its complications, particularly in studying the immunopathophysiology of GVHD. He has served as principal investigator or co-investigator on over 100 clinical trials including multiple initiatives sponsored by numerous national transplant organizations including SWOG, CIBMTR, ISCT, NMDP and BMT CTN. Within the BMT CTN, he serves on the Steering committee, chaired the Regimen Related Toxicity Committee, was a member of the GVHD Committee and served as the principal investigator for the BMT CTN on the first multicenter, stem cell transplant trial for patients with advanced chronic lymphocytic leukemia (BMT CTN 0804).
He also served on the writing committee for the first national multicenter, randomized trial between conventional and reduced intensity transplantation (BMT CTN 0901) and for transplantation for HIV associated malignancies. He currently serves as Chair of the Regimen Related Toxicity Strategic Planning Committee of the BMT CTN for the planned State of the Science Symposium, to define cell therapy and transplant clinical trials over the next 5 years.
A special interest has been the intersection of transplantation and health policy; he has served as consultant to the Oregon Health Resource Commission assessing indications for autologous transplantation and analyzing efficacy of reduced intensity allogeneic transplantation as a standard of care for adults with hematologic malignancies. He also has been an active member of the Health Policy working committee of the CIBMTR, served as a member of the ASBMT reimbursement committee and served as Chair of the NMDP financial working group for their system capacity initiative regarding transplantation expansion and most recently is Chair of the Health Economics SIG for ASTCT. At OHSU, he had maintained a laboratory focused on basic and preclinical models focused on how to reduce the risks for morbidity and mortality associated with graft versus host disease.
Most recently, his focus has been on the toxicity and efficacy of immune effector cell therapy. He has opened IEC multiple trials, assisted in the generation/ writing of new emerging trials utilizing CART and NK cells for a variety of disease indications and was the Chair of the Scientific Steering Committee for the Juliet trial that led to the approval of tisagenlecleucel for advanced diffuse large B cell lymphoma.
Education and training
-
Degrees
- M.D., 1979, Harvard Medical School
-
Residency
- University Hospitals of Cleveland, 1981
-
Fellowship
- Immunology, Dana-Farber Cancer Institute, 1985
-
Certifications
- American Board of Internal Medicine (internal medicine), 1982
Memberships and associations:
- American Society of Hematology
Publications
Elsevier pure profilePublications
Sociodemographic Factors Influencing Access to Chimeric Antigen T-Cell Receptor Therapy for Patients With Non-Hodgkin Lymphoma
Clinical Lymphoma, Myeloma and LeukemiaA model of lymphocryptovirus-associated post-transplant lymphoproliferative disorder in immunosuppressed Mauritian cynomolgus macaques
PLoS pathogensA phase II trial of netupitant/palonosetron for prevention of chemotherapy-induced nausea/vomiting in patients receiving BEAM prior to hematopoietic cell transplantation
Journal of Oncology Pharmacy PracticeClinical Practice Recommendations for Hematopoietic Cell Transplantation and Cellular Therapies in Follicular Lymphoma
Transplantation and Cellular TherapyCost-Effectiveness of Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation for Older Patients with High-Risk Myelodysplastic Syndrome
JCO Oncology Practice“Don’t keep me waiting”
Blood AdvancesGalectin-3 predicts acute GvHD and overall mortality post reduced intensity allo-HCT
Bone marrow transplantationHealth care costs among patients with hematologic malignancies receiving allogeneic transplants
Blood AdvancesMedicare Utilization and Cost Trends for CAR T Cell Therapies Across Settings of Care in the Treatment of Diffuse Large B-Cell Lymphoma
Advances in TherapyOptimizing the post-CAR T monitoring period in recipients of axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel
Blood AdvancesThe impact of omidubicel on immune reconstitution and infections in cord blood transplant patients
Expert Opinion on Biological TherapyAllogeneic Hematopoietic Cell Transplantation Improves Outcome in Myelodysplastic Syndrome Across High-Risk Genetic Subgroups
Journal of Clinical OncologyAllogeneic immunity clears latent virus following allogeneic stem cell transplantation in SIV-infected ART-suppressed macaques
ImmunityAnakinra for Refractory Cytokine Release Syndrome or Immune Effector Cell-Associated Neurotoxicity Syndrome after Chimeric Antigen Receptor T Cell Therapy
Transplantation and Cellular TherapyChimeric antigen receptor T-cell therapy yields similar outcomes in patients with and without cytokine release syndrome
Blood AdvancesClash of the titans
Nature Reviews Clinical OncologyComparison and validation of the 2022 European LeukemiaNet guidelines in acute myeloid leukemia
Blood AdvancesDay 4 collection of granulocyte colony-stimulating factor-mobilized HLA-matched sibling donor peripheral blood allografts demonstrates no long-term increase in chronic graft-versus-host disease or relapse rates
CytotherapyEstimating the Lifetime Medical Cost Burden of an Allogeneic Hematopoietic Cell Transplantation Patient
Transplantation and Cellular TherapyHealth-Related Quality of Life Following Allogeneic Hematopoietic Cell Transplantation with Omidubicel versus Umbilical Cord Blood
Transplantation and Cellular TherapyHospitalization and Healthcare Resource Utilization of Omidubicel-Onlv versus Umbilical Cord Blood Transplantation for Hematologic Malignancies
Transplantation and Cellular TherapyIdentifying an optimal fludarabine exposure for improved outcomes after axi-cel therapy for aggressive B-cell non-Hodgkin lymphoma
Blood AdvancesLong-term Outcomes After Hematopoietic Cell Transplant in Peripheral T-Cell Lymphoma – The Oregon Health and Science University Experience
Clinical Lymphoma, Myeloma and LeukemiaLow toxicity and excellent outcomes in patients with DLBCL without residual lymphoma at the time of CD19 CAR T-cell therapy
Blood Advances